Dr Gay speaks with ecancer at EHA 2018 about updated data from the FORTE trial, looking at newly diagnosed myeloma patients treated with carfilzomib plus lenalidomide or cyclophosphamide.

She states that one of the primary objectives of the trail was response rate after the induction phase and both regiments of patients were highly effective with roughly 90% of patients in both arms achieving a partial response.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.